TSW
TLSI icon

Thompson Siegel & Walmsley’s TriSalus Life Sciences TLSI Stock Holding History

Thompson Siegel & Walmsley’s Portfolio TLSI Stock Details TLSI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.44M Sell
536,534
-47,040
-8% -$187K 0.04% 286
2026
Q1 		$2.33M Buy
+583,574
New +$2.86M 0.04% 275

Other funds holding TLSI

FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Cerity Partners
Cerity Partners New York $82.7B AUM 28.53% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
WPC
White Pine Capital Bloomington, Minnesota $423M AUM 67.01% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return

Thompson Siegel & Walmsley's TLSI Position: Q2 2026 in Review

Thompson Siegel & Walmsley reduced its TriSalus Life Sciences (TLSI) stake by 8.1% in Q2 2026, selling an estimated $187K and leaving 536,534 shares worth $2.44M. The position accounts for 0.04% of the portfolio, ranked #286.

Thompson Siegel & Walmsley first reported a position in TLSI in Q1 2026 and has held it in 2 quarters since. 79 funds tracked by Wall St. Rank hold TLSI as of Q2 2026.

  • Thompson Siegel & Walmsley held 536,534 shares of TriSalus Life Sciences worth $2.44M as of Q2 2026.
  • Thompson Siegel & Walmsley sold 47,040 TriSalus Life Sciences shares in Q2 2026, an estimated $187K.
  • TriSalus Life Sciences made up 0.04% of Thompson Siegel & Walmsley's portfolio in Q2 2026, its #286 holding.
  • Thompson Siegel & Walmsley first reported a position in TriSalus Life Sciences in Q1 2026 and has held it in 2 quarters since.
  • 79 funds tracked by Wall St. Rank held TriSalus Life Sciences as of Q2 2026.

Based on Thompson Siegel & Walmsley's 13F filing for Q2 2026, filed 11 Aug 2026.